Berger v. Personal Products, Inc.
| Decision Date | 20 September 1990 |
| Docket Number | No. 56098-6,56098-6 |
| Citation | 797 P.2d 1148,115 Wn.2d 267 |
| Court | Washington Supreme Court |
| Parties | , Prod.Liab.Rep. (CCH) P 12,689 Ernest BERGER, Personal Representative of the Estate of Sheila Berger, Appellant, v. PERSONAL PRODUCTS, INC., a foreign corporation, aka and/or merged with Johnson & Johnson Baby Products, a foreign corporation; and Johnson & Johnson Products, Inc., a foreign corporation; and Johnson & Johnson, Inc., a foreign corporation, Respondents. En Banc |
Rush, Hannual & Harkins, William J. Rush and Daniel R. Kyler, Tacoma, for appellant.
Karr, Tuttle, Campbell, Susan J. Robinson, Gregory C. Sisk, Seattle and Arter & Hadden, George Gore, and Victoria L. Vance, Cleveland, Ohio, of counsel, for respondents.
Appellant Ernest Berger, as personal representative of the estate of Sheila Berger, deceased, appeals from a partial summary judgment of the Yakima County Superior Court dismissing his product liability action against respondent Personal Products, Inc. We affirm the trial court.
The sole question we consider is whether under 21 U.S.C. § 360k(a) and 21 C.F.R. § 808.1(b) federal law preempts a state tort action based on the claims of inadequate warnings and instructions about the risk of contracting toxic shock syndrome associated with tampon use when the product complies with federal labeling requirements under 21 C.F.R. § 801.430. Appellant Berger does not dispute respondent's compliance with those regulations. We answer that federal law does preempt a state tort action under these circumstances.
On January 4, 1984, Ms. Sheila Berger, age 20, died of toxic shock syndrome alleged to have been contracted as a result of using respondent's product, "o.b. tampons." 1 In his claims against Respondent Personal Products, Inc., Appellant Berger alleged that Personal Products' tampon was unreasonably dangerous because of its faulty manufacture, faulty design, and inadequate warnings and instructions about the risk of contracting toxic shock syndrome.
Respondent Personal Products, Inc., moved for summary judgment on the claim of inadequate warnings and instructions, arguing that federal statutes and regulations preempt any state tort action based upon the adequacy of warnings when the product complies with federal labeling requirements under 21 C.F.R. § 801.430.
The trial court, the Honorable Bruce P. Hanson, Yakima County Superior Court, granted the motion for partial summary judgment, holding that, under 21 U.S.C. § 360k(a) and 21 C.F.R. § 808.1(b) relating to preemption, federal law preempts a state tort action on this issue. The trial court denied a request by Appellant Berger to enter a final judgment on the warnings and instructions issues pursuant to CR 54(b). Appellant Berger then stipulated to dismissal with prejudice of his remaining claims.
Appellant Berger claims that federal statutes and regulations do not preempt a state tort action based on the adequacy of warnings and instructions.
Respondent Personal Products, Inc., asserts that the regulations promulgated by the Food and Drug Administration governing labeling requirements of tampons found in 21 C.F.R. § 801.430 preempt state tort law on this issue under 21 U.S.C. § 360k(a) and 21 C.F.R. § 808.1(b).
The doctrine of federal preemption is derived from the supremacy clause of the United States Constitution, article 6, clause 2. Federal law preempts state law when Congress intends to occupy a given field, when state law directly conflicts with federal law, or when state law would hinder accomplishment of the full purposes and objectives of the federal law. 2 Preemption may be either express or implied, and is compelled whether Congress' command is explicitly stated in the statute's language or implicitly contained in its structure and purpose. Federal regulations have the same preemptive effect as federal statutes. 3
In 1976 Congress enacted extensive and comprehensive amendments to the Food, Drug and Cosmetic Act of 1938, 21 U.S.C. § 301 et seq., which became known as the Medical Device Amendments of 1976, 90 Stat. 539, 21 U.S.C. § 360c-k. Under the amendments, all medical devices intended for human use are required to be classified according to their potential risk in order to insure that each product receives the most appropriate form of regulatory control. The Food and Drug Administration classified tampons as Class II (performance standards) medical devices. 4
Respondent Personal Products, Inc., asserts that section 360k(a) of the Medical Device Amendments expressly preempts any warnings or instructions claims based on state tort law. That section provides in relevant part:
[N]o State or political subdivision of a State may establish or continue in effect with respect to a device intended for human use any requirement--
(1) which is different from, or in addition to, any requirement applicable under this chapter to the device, and
(2) which relates to the safety or effectiveness of the device or to any other matter included in a requirement applicable to the device under this chapter.
Regulations promulgated by the Food and Drug Administration pursuant to this statute reflect this expression of intent to preempt state law.
[Section 360k(a) ] prescribes a general rule that ... no State or political subdivision of a State may establish or continue in effect any requirement with respect to a medical device intended for human use having the force and effect of law (whether established by statute, ordinance, regulation, or court decision ), which is different from, or in addition to, any requirement applicable to such device under any provision of the act which relates to the safety or effectiveness of the device or to any other matter included in a requirement applicable to the device under the act.[ 5
(Italics ours.)
In 1982, in response to the discovered association between toxic shock syndrome and tampon use, the Food and Drug Administration adopted labeling requirements for tampons. The regulations required the following consumer information to appear "prominently and legibly, in a package insert or on the package, in terms understandable by the layperson": 6
1. The warning signs of Toxic Shock Syndrome and what to do if the warning signs appear;
2. The statistical risk of Toxic Shock Syndrome to women using tampons;
3. The advisability of using tampons with the minimum absorbency needed to control menstrual flow; 4. The potential for avoiding the risk of getting tampon-associated Toxic Shock Syndrome by not using tampons and the potential for possibly reducing the risk of getting toxic shock syndrome by alternating tampon use with sanitary napkin use during menstrual periods;
5. The need to seek medical attention before again using tampons if Toxic Shock Syndrome warning signs have occurred in the past, or if women have any questions about Toxic Shock Syndrome or tampon use. 7
In addition to the information to be provided in a package insert, the following "alert statement" must appear "prominently and legibly on the package label":
ATTENTION: Tampons are associated with Toxic Shock Syndrome (TSS). TSS is a rare but serious disease that may cause death. Read and save the enclosed information.[ 8
United States District Courts addressing this same issue in recent years have almost uniformly held that federal law preempts state tort actions under these circumstances. 9 The United States Court of Appeals for the Fifth Circuit has similarly ruled. In Moore v. Kimberly-Clark Corp., 10 that court affirmed the District Court's grant of summary judgment in favor of the defendant tampon manufacturer with respect to plaintiff's warnings and instructions claims. In doing so, the court concluded that state law claims based on inadequate labeling and warning statements are preempted 11 by 21 U.S.C. § 360k and 21 C.F.R. § 808.1(b). 12
The court in Moore noted that:
The FDA did not intend to preempt all state laws and regulations pertaining to tampons. This is made clear in [21 C.F.R. § 808.1(d) 13 which provides that "[s]tate or local requirements are preempted only when the Food and Drug Administration has established specific counterpart regulations or there are other specific requirements applicable to a particular device under the act...." The relevant requirements applicable under § 360k are set forth in 21 C.F.R. §§ 801.430, 884.5460, and 884.5470, which declare that tampons are a medical device covered by the Act and outline the liability and warning requirements with respect to TSS [toxic shock syndrome]. 14
The United States District Court for the District of South Carolina in Stewart v. International Playtex, Inc., 15 granted partial summary judgment for a defendant tampon manufacturer on the ground that the Medical Device Amendments expressly preempted state law. The court in Stewart rejected the contention that state tort law should not be considered a state law "requirement" within the meaning of the Medical Device Amendments preemption provision defined in 21 C.F.R. § 808.1(b), statingat pages 909-10:
On its face, this definition encompasses the actions of a court of law entering judgment against the defendant for compensatory and punitive damages based upon "inadequate warnings". The FDA has therefore determined that a state's common law--to the extent it attempts to regulate matters already addressed by the FDA--shall be considered a § 360k "requirement". South Carolina tort law is, therefore not exempt from § 360k.
At least one reported case does not recognize federal preemption in a product liability action based on inadequate warnings and instructions on the risk associated with tampon use. In Muzatko v. International Playtex, Inc., 16 the United States District Court for the Eastern District of Wisconsin concluded that the Food and Drug Administration's toxic shock syndrome warnings regulations did not rise to the level of a...
To continue reading
Request your trial
-
Washington State Physicians Ins. Exchange & Ass'n v. Fisons Corp.
...that there are cases decided under FDA regulation where the federal law does preempt state tort law. See Berger v. Personal Prods., Inc., 115 Wash.2d 267, 797 P.2d 1148 (1990), cert. denied, --- U.S. ----, 111 S.Ct. 1584, 113 L.Ed.2d 649 (1991). However, those cases involve the express pree......
-
National Bank of Commerce of El Dorado v. Kimberly-Clark Corp.
...Ga. 850, 412 S.E.2d 526 (1991); Lulov v. Tambrands, Inc., 198 A.D.2d 479, 604 N.Y.S.2d 206 (App.Div.1993); Berger v. Personal Prods., Inc., 115 Wash.2d 267, 797 P.2d 1148 (1990), cert. denied, 499 U.S. 961, 111 S.Ct. 1584, 113 L.Ed.2d 649 (1991). National Bank acknowledges the weight of the......
-
Bravman v. Baxter Healthcare Corp.
...Cv. No. 87-152, 1989 WL 8812, *1, 1989 U.S.Dist. LEXIS 800, at *2 (E.D.Ky. Jan. 26, 1989). See also Berger v. Personal Prods., Inc., 115 Wash.2d 267, 797 P.2d 1148, 1151-52 (1990), cert. denied, 499 U.S. 961, 111 S.Ct. 1584, 113 L.Ed.2d 649 18 The Stamps Court also re-construed the Fifth Ci......
-
Hue v. Farmboy Spray Co., Inc.
...case was decided, this Court interpreted the term "requirements" in a federal preemption provision in Berger v. Personal Products, Inc., 115 Wash.2d 267, 271-75, 797 P.2d 1148 (1990), cert. denied, 499 U.S. 961, 111 S.Ct. 1584, 113 L.Ed.2d 649 (1991). We held in Berger that the federal Medi......